Achieve Life Sciences Q1 loss narrows more than expected

Achieve Life Sciences

12/05/2026 13:32

Overview

US specialty pharmaceutical firm's Q1 adjusted EPS loss beat analyst expectations

Company closed private placement of up to $354 mln, including $180 mln upfront

Achieve appointed new CEO and expanded board, advancing U.S. manufacturing partnership

Outlook

Company expects to receive FDA Complete Response Letter on or before June 20, 2026

Achieve plans to resubmit New Drug Application in Q4 2026 with new manufacturing partner

Company targets U.S. commercial launch of cytisinicline in first half of 2027

Result Drivers

CAPITAL RAISE - Closed private placement of up to $354 mln to fund clinical trial, commercialization, and working capital needs

LEADERSHIP TRANSITION - Appointed new CEO and expanded board, reorganized commercial leadership ahead of planned launch

MANUFACTURING PARTNERSHIP - Advanced U.S.-based manufacturing by partnering with Adare Pharma Solutions and completing technology transfer

Company press release: ID:nGNX984XM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
Beat
-$0.19
-$0.31 (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Achieve Life Sciences Inc is $12.00, about 114.7% above its May 11 closing price of $5.59

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)